Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ: DARE) reported its Q1 2024 financials and company updates. Key developments include the ongoing Phase 3 study of Ovaprene®, a hormone-free contraceptive, and the successful end-of-Phase 2 meeting with the FDA for Sildenafil Cream, aimed at treating female sexual arousal disorder. Financial highlights show a decrease in Q1 2024 R&D expenses to $3.3 million from $5.0 million in Q1 2023, and a $22 million non-dilutive financing deal secured in April 2024. Cash reserves stood at $3.6 million as of March 31, 2024. The company's collaboration with Organon on XACIATO™ continues, with further milestones anticipated in 2024.
Daré Bioscience, Inc. will host a conference call and webcast on May 14, 2024, to discuss its financial results for Q1 2024. The company is a leader in women's health innovation, with details on how to access the call provided in the press release.
Daré Bioscience, Inc. (NASDAQ: DARE) has been chosen as a spoke member of the Investor Catalyst Hub, part of the nationwide ARPA-H network. This selection provides Daré with access to funding, networking opportunities, and the ability to influence research priorities in women's health.
Daré Bioscience secured $22 million in non-dilutive strategic royalty financing to advance Phase 3 first-in-category women’s health product candidates through key catalysts. The transaction with XOMA provides significant capital for Daré to focus on advancing Ovaprene® and Sildenafil Cream, 3.6%. This accelerates potential cash flows and shareholder value, showcasing the company's commitment to delivering value for all stakeholders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.